Aktiesnakken — Juni 2010
-
min fornemmelse er at mange analytikere gerne vil give genmab en chance til, nu må vi altså tage den
-
gen er i plus:-)
-
faneme flot efter det kaotiske CC
-
det må de jo vide at Genmab ikke kan
-
ja arzerra er vel så tæt på en blockbuster man kan komme uden at være det
-
men hvis GSK var interesseret hvorfor lod de så ikke Genmab producere arzerra på fabrikkan
-
hvorfor vælge en ekstern leverandør til det. Det bløder os jo max
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
